Heron Therapeutics (HRTX) reported $34.67 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.1%. EPS of -$0.02 for the same period compares to -$0.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $32.5 million, representing a surprise of +6.68%. The company delivered an EPS surprise of +75.00%, with the consensus EPS estimate being -$0.08.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...